NCT06646562View on ClinicalTrials.gov

Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2027

Conditions
HIV-1 Infected Adults with Controlled Viremia
Interventions
DRUG

Cabotegravir LA + Rilpivirine LA

Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.

Trial Locations (8)

30003

RECRUITING

Hospital General Universitario Reina Sofia, Murcia

30008

NOT_YET_RECRUITING

Hospital General Universitario Morales Meseguer, Murcia

30100

NOT_YET_RECRUITING

Hospital Clinico Universitario Virgen de la Arrixaca Murcia, Murcia

30202

NOT_YET_RECRUITING

Hospital General Universitario Santa Lucía, Cartagena

30739

NOT_YET_RECRUITING

Hospital General Universitario Los Arcos del Mar Menor, Pozo-Aledo

30813

NOT_YET_RECRUITING

Hospital Universitario Rafael Mendéz de Lorca, Lorca

03203

NOT_YET_RECRUITING

Hospital General Universitario de Elche, Elche

03570

NOT_YET_RECRUITING

Hospital Marina Baixa, Villajoyosa

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER

NCT06646562 - Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. | Biotech Hunter | Biotech Hunter